Guido Koch

Guido Koch is a highly experienced professional in the field of drug discovery and chemistry, currently serving as a Scientific Advisor at eMolecules since January 2023. As Co-Founder and CEO of Amphilix, established in August 2020, Guido Koch is focusing on the development of small molecular chimeras using a unique linker platform based on Spirochem AG technology. Additionally, since June 2020, Guido Koch has been a Board Member at Synple, where automated synthesizers are being developed to enhance the efficiency of molecular synthesis. Prior experience includes serving as Chief Operating Officer at TOPADUR PHARMA AG, where Guido Koch led drug development initiatives, and holding various leadership roles at Novartis Institutes for BioMedical Research (NIBR) for over two decades, including Director of Global Discovery Chemistry. Guido Koch's educational background includes advanced studies in management, bioentrepreneurship, and organic synthesis from prestigious institutions, including ETH Zürich and Caltech.